Xyzal Allergy 24Hr is owned by Chattem Sanofi.
Xyzal Allergy 24Hr contains Levocetirizine Dihydrochloride.
Xyzal Allergy 24Hr has a total of 1 drug patent out of which 0 drug patents have expired.
Xyzal Allergy 24Hr was authorised for market use on 31 January, 2017.
Xyzal Allergy 24Hr is available in solution;oral dosage forms.
The generics of Xyzal Allergy 24Hr are possible to be released after 16 October, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8633194||CHATTEM SANOFI||Pharmaceutical composition of piperazine derivatives|| |
(4 years from now)
Market Authorisation Date: 31 January, 2017
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic